1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Immutep LAG-3 Inhibitor May Have Path Forward

 
• By Joseph Haas

After missing statistical significance in PD-L1+ head-and-neck cancer, Immutep presents data showing eftilagimod with Keytruda can offer efficacy in PD-L1-negative patients.

3d illustration of T cells attacking a cancer cell
Immutep thinks its LAG-3 inhibitor can improve immune response for PD-1 agents

Immutep S.A. thinks it may have identified a niche opportunity for its LAG-3 immunotherapy in head-and-neck cancer, albeit from a small and non-controlled sample of a Phase IIb study that earlier this year yielded uninspiring data. The Australian company and analysts are contending that eftilagimod alfa, in combination with Merck & Co., Inc.’s Keytruda (pembrolizumab), might offer a chemotherapy-sparing regimen that would offer comparable efficacy in a tough-to-treat patient population with better safety and tolerability.

Key Takeaways

  • Hoping to find a path forward after a disappointing Phase II trial in head-and-neck cancer, Immutep finds that its LAG-3 agent combined with Keytruda bests Keytruda monotherapy in PD-L1-negative patients

At the European Society of Medical Oncology virtual plenary session on 11 July, Immutep reported that eftilagimod produced a 35

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.